Compatibility of betamethasone 17-valerate and ketoconazole foam formulations in combination topical therapy

hanafi tanojo,jon lenn,xinfan huang

DOI: https://doi.org/10.1016/j.jaad.2003.11.019

IF: 15.487

2011-01-01

Journal of the American Academy of Dermatology

Abstract:Combination therapy often becomes necessary to enhance efficacy in the treatment of seborrheic dermatitis. As the concomitant use of antifungals with topical corticosteroids increase, it is of interest to investigate the effects of these combinations. This is especially worthwhile when vehicles contain different excipients known to influence the mode of delivery of the drugs. Two foam formulations, one containing betamethasone valerate (BMV) and the other containing ketoconazole, are applied sequentially and investigated for the in vitro skin permeation profile of either active component. Objective: The purpose of the study is to examine the permeation profile of two active compounds in foam, BMV and ketoconazole, when applied concomitantly. Method: In vitro permeation through human split-thickness skin (∼0.25mm) was measured using flow-through diffusion cells. BMV and ketoconazole in their respective foam formulations were applied at 5 minute intervals, either BMV or ketoconazole first. The formulations were tested on four replicate sections from at least three human donors (n = 12). Application of each formulation alone was used as reference. Receptor fluid was collected at 4-hour intervals. At 24 hours after application, the skin surface was washed and the membrane is split into epidermis and dermis to measure drug content within these layers. The drug content in samples was measured by HPLC. Results and Conclusions: Co-application of ketoconazole and BMV formulations will be investigated to determine the permeation of these components. As both formulations are foam based, it will be interesting to see whether any synergistic effects between the two applications will occur.